123 related articles for article (PubMed ID: 28326956)
21. The General Expression Analysis of WTX Gene in Normal and Cancer Tissues.
Zhang YY; Wang QM; Niu HL; Liu X; Zhang QL
Pathol Oncol Res; 2017 Apr; 23(2):439-446. PubMed ID: 28032309
[TBL] [Abstract][Full Text] [Related]
22. Characterization of 17.94, a novel anaplastic Wilms' tumor cell line.
Brown KW; Charles A; Dallosso A; White G; Charlet J; Standen GR; Malik K
Cancer Genet; 2012 Jun; 205(6):319-26. PubMed ID: 22749038
[TBL] [Abstract][Full Text] [Related]
23. Correlations between Histological and Array Comparative Genomic Hybridization Characterizations of Wilms Tumor.
Chiang MR; Kuo CW; Wang WC; Hou TC; Kuo CY; Lu MY; Lai YC
Pathol Oncol Res; 2019 Jul; 25(3):1199-1206. PubMed ID: 30671724
[TBL] [Abstract][Full Text] [Related]
24. Functional characterization of Wilms tumor-suppressor WTX and tumor-associated mutants.
Kim MK; Min DJ; Rabin M; Licht JD
Oncogene; 2011 Feb; 30(7):832-42. PubMed ID: 20956941
[TBL] [Abstract][Full Text] [Related]
25. Wilms tumor genetics: a new, UnX-pected twist to the story.
Huff V
Cancer Cell; 2007 Feb; 11(2):105-7. PubMed ID: 17292822
[TBL] [Abstract][Full Text] [Related]
26. Clinical and molecular description of a Wilms tumor in a patient with tuberous sclerosis complex.
Spreafico F; Notarangelo LD; Schumacher RF; Savoldi G; Gamba B; Terenziani M; Collini P; Fasoli S; Giordano L; Luisa B; Porta F; Massimino M; Radice P; Perotti D
Am J Med Genet A; 2011 Jun; 155A(6):1419-24. PubMed ID: 21567926
[TBL] [Abstract][Full Text] [Related]
27. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis.
Jenkins ZA; van Kogelenberg M; Morgan T; Jeffs A; Fukuzawa R; Pearl E; Thaller C; Hing AV; Porteous ME; Garcia-Miñaur S; Bohring A; Lacombe D; Stewart F; Fiskerstrand T; Bindoff L; Berland S; Adès LC; Tchan M; David A; Wilson LC; Hennekam RC; Donnai D; Mansour S; Cormier-Daire V; Robertson SP
Nat Genet; 2009 Jan; 41(1):95-100. PubMed ID: 19079258
[TBL] [Abstract][Full Text] [Related]
28. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
Roberts DJ; Haber D; Sklar J; Crum CP
Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
[TBL] [Abstract][Full Text] [Related]
29. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
[TBL] [Abstract][Full Text] [Related]
30. [The tumor suppressor gene WTX, mutated in Wilms tumours, is a member of the beta-catenin destruction complex].
Angers S
Med Sci (Paris); 2007 Nov; 23(11):1025-7. PubMed ID: 18021721
[No Abstract] [Full Text] [Related]
31. Berberine inhibits Wilms' tumor cell progression through upregulation of Wilms' tumor gene on the X chromosome.
Liu Y; Liu S
Mol Med Rep; 2013 Nov; 8(5):1537-41. PubMed ID: 24002362
[TBL] [Abstract][Full Text] [Related]
32. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
33. Constitutional WT1 mutations in Wilms' tumor patients.
Diller L; Ghahremani M; Morgan J; Grundy P; Reeves C; Breslow N; Green D; Neuberg D; Pelletier J; Li FP
J Clin Oncol; 1998 Nov; 16(11):3634-40. PubMed ID: 9817285
[TBL] [Abstract][Full Text] [Related]
34. Wilms tumor: an update.
Al-Hussain T; Ali A; Akhtar M
Adv Anat Pathol; 2014 May; 21(3):166-73. PubMed ID: 24713986
[TBL] [Abstract][Full Text] [Related]
35. A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Children's Oncology Group study.
Armstrong AE; Gadd S; Huff V; Gerhard DS; Dome JS; Perlman EJ
PLoS One; 2018; 13(12):e0208936. PubMed ID: 30543698
[TBL] [Abstract][Full Text] [Related]
36. Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target.
Pode-Shakked N; Harari-Steinberg O; Haberman-Ziv Y; Rom-Gross E; Bahar S; Omer D; Metsuyanim S; Buzhor E; Jacob-Hirsch J; Goldstein RS; Mark-Danieli M; Dekel B
Oncogene; 2011 Apr; 30(14):1664-80. PubMed ID: 21472018
[TBL] [Abstract][Full Text] [Related]
37. Is WTX a suitable target for cancer therapy?
Perotti D; Radice P
Pediatr Blood Cancer; 2011 Apr; 56(4):682. PubMed ID: 21298763
[No Abstract] [Full Text] [Related]
38. The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity.
Rivera MN; Kim WJ; Wells J; Stone A; Burger A; Coffman EJ; Zhang J; Haber DA
Proc Natl Acad Sci U S A; 2009 May; 106(20):8338-43. PubMed ID: 19416806
[TBL] [Abstract][Full Text] [Related]
39. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
Fukuzawa R; Heathcott RW; More HE; Reeve AE
J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
[TBL] [Abstract][Full Text] [Related]
40. Responsiveness of chemotherapy based on the histological type and Wilms' tumor suppressor gene mutation in bilateral Wilms' tumor.
Shibata R; Takata A; Hashiguchi A; Umezawa A; Yamada T; Hata J
Pathol Int; 2003 Apr; 53(4):214-20. PubMed ID: 12675764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
